SCHEMBL26565468

SCHEMBL26565468

CCc1cc(C(O)c2ccc3cncc(-c4ccccc4)c3c2)ccc1Br

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC22A12 Q96S37 12/20 0.41
CCNC P24863 2/20 0.41
CDK8 P49336 2/20 0.41
NTSR1 P30989 1/20 0.35
PLK4 O00444 1/20 0.34
AURKA O14965 1/20 0.34
DAPK3 O43293 1/20 0.34
CHEK2 O96017 1/20 0.34
CDK1 P06493 1/20 0.34
PIM1 P11309 1/20 0.34
PRKACA P17612 1/20 0.34
CDK2 P24941 1/20 0.34
MAPK9 P45984 1/20 0.34
CSNK1D P48730 1/20 0.34
GSK3A P49840 1/20 0.34
GSK3B P49841 1/20 0.34
RPS6KA3 P51812 1/20 0.34
CSNK2A1 P68400 1/20 0.34
DYRK1A Q13627 1/20 0.34
AURKB Q96GD4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26565466 0.84 CCNC (0.37) SLC22A12CCNCCDK8NTSR1DYRK1A
SCHEMBL10138248 0.67 SLC22A12 (0.56) SLC22A12CCNCCDK8PLK4AURKA
SCHEMBL7048885 0.65 CA1 (0.41) CYP3A4CYP2D6CYP2C19
SCHEMBL17981126 0.64 TDP1 (0.50) SLC22A12PLK4AURKADAPK3CHEK2
SCHEMBL2755399 0.63 LMNA (0.44)
SCHEMBL455838 0.63 DCLRE1A (0.43) CYP1A2
SCHEMBL21392388 0.63 UGT2B7 (0.44) SLC22A12CCNCCDK8CYP11B1CYP11B2
SCHEMBL29501875 0.62 PRKCZ (0.72) CCNCCDK8AURKBCYP11B1CYP11B2
SCHEMBL6243938 0.62 PRKCZ (0.72) CCNCCDK8AURKBCYP11B1CYP11B2
SCHEMBL31453996 0.62 L3MBTL1 (0.43) NTSR1CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12018011-B2 Macrocyclic compounds and compositions, and methods of preparing and using the same KURA ONCOLOGY, INC. (US) 2024-06-25 US disclosed
US-20230322711-A1 MACROCYCLIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF PREPARING AND USING THE SAME WUXI APPTEC (HONG KONG) LIMITED (CN) 2023-10-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12018011-B2 Macrocyclic compounds and compositions, and methods of preparing and using the same FNTA, FDPS, GGPS1 SLC22A12 3616/4885CCNC 599/4885CDK8 2946/4885
US-20230322711-A1 MACROCYCLIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF PREPARING AND USING THE SAME FNTA, FDPS, GGPS1 SLC22A12 3616/4885CCNC 599/4885CDK8 2946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.